The stock recently changed hands at $14.53, a significant drop from its opening price of $14.88. This performance follows the company’s decision to increase the scale of its offering, ultimately selling 10.6 million shares at $16 each. Management had originally planned to issue roughly 9.4 million shares within a price range of $15 to $17. The market's tepid reaction signals caution toward the biotech sector, even as Bambusa successfully secured more capital than originally outlined in its regulatory filings.
Bambusa Therapeutics Slumps in Trading Debut
Investors cooled on Bambusa Therapeutics during the company's first day of public trading Friday, pushing shares down more than 9% following an upsized initial public offering. The Boston-based biopharmaceutical firm, which develops clinical-stage treatments, struggled to maintain momentum despite exceeding its initial target for share volume.
Comments (0)
No comments yet. Be the first!